Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...
For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased ris ...
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.
Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...
A new study published in the recent issue of The Journal of Investigative Dermatology found the connection between childhood ...
Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...
Q4 2024 total revenues reached $1.2 billion, with $1 billion in product revenues. Jakafi's Q4 net revenue increased 11% year-over-year to $773 million, while Opzelura's Q4 revenue grew 48% to $162 ...
A 0.15% once-daily roflumilast cream improved symptoms of atopic dermatitis (AD) across multiple endpoints, according to ...
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback